Online inquiry

IVTScrip™ mRNA-Anti-CD38, HuMax-CD38(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ8659MR)

This product GTTS-WQ8659MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD38 gene. The antibody can be applied in Multiple myeloma (MM), AL amyloidosis research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001775.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 952
UniProt ID P28907
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD38, HuMax-CD38(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ8659MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8202MR IVTScrip™ mRNA-Anti-SLC39A6, hLIV22(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA hLIV22
GTTS-WQ9309MR IVTScrip™ mRNA-Anti-HLA, IMP-321(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA IMP-321
GTTS-WQ111MR IVTScrip™ mRNA-Anti-EGFR, 11F8(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 11F8
GTTS-WQ6003MR IVTScrip™ mRNA-Anti-ITGAV&ITGB3, CNTO 095(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CNTO 095
GTTS-WQ6218MR IVTScrip™ mRNA-Anti-RABVgp4, CR4098(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CR4098
GTTS-WQ11562MR IVTScrip™ mRNA-Anti-CD276, MG-A271(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MG-A271
GTTS-WQ1635MR IVTScrip™ mRNA-Anti-F10&F9, ACE-910(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ACE-910
GTTS-WQ13152MR IVTScrip™ mRNA-Anti-NGF, PF-04383119(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA PF-04383119
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW